Genexine Revenue

Biotechnology Research • 172, Magokjungang-ro, Korea, Republic of • 21-50 Employees

Genexine revenue & valuation

Annual revenue	$9,408,840
Revenue per employee	$201,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$30,200,000
Total funding	No funding

Key Contacts at Genexine

Joo Hyoung Lee

Director

Eunho Choi

Director

Company overview

Headquarters	172, Magokjungang-ro, Korea, Republic of
Phone number	+82316283200
Website	genexine.com
NAICS	541714
SIC	283
Keywords	Oncology, Immuno-Oncology, TPD, Growth Hormone, Anemia, Cancer Vaccine, Atopic Dermatitis, Glp-1, Nanobody, Protac, First-In-Class, Biobetter, Protein Degrader, Bioprotac, Interleukin-7, Long Acting Drugs
Founded	1999
Employees	21-50
Socials

Genexine Email Formats

Genexine uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@genexine.com), used 47.1% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@genexine.com	47.1%
{first initial}.{last name}	j.doe@genexine.com	41.2%
{first initial}{second initial}.{last name}	jo.doe@genexine.com	5.9%
{first name}	john@genexine.com	5.9%

About Genexine

Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation . Its primary technology platforms are Therapeutic DNA vaccine and hyFc® long-acting technology and bioPROTAC. The company has multiple products in clinical development including several undergoing Phase 3 registrational trials. The company's proprietary pipeline includes GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. in 2024, Genexine has completed a merger with 'EPD biotherapeutics' and acquired future focusing new modality 'bioPROTAC' platform technology which now in pre-clinical development focusing on oncology. The company has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide. For more information about Genexine, please visit at www.genexine.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Manager

Vice President

Employees by Department

Genexine has 13 employees across 5 departments.

Departments

Number of employees

Funding Data

Genexine has never raised funding before.

Genexine Tech Stack

Discover the technologies and tools that power Genexine's digital infrastructure, from frameworks to analytics platforms.

jQuery

JavaScript libraries

Nginx

Reverse proxies

Slick

JavaScript libraries

fullPage.js

JavaScript libraries

Open Graph

Miscellaneous

SweetAlert2

JavaScript libraries

Google Maps

Maps

scrollreveal

JavaScript libraries

Unpkg

CDN

Google Font API

Font scripts

Frequently asked questions

Genexine is located in 172, Magokjungang-ro, KR.

You can reach Genexine at +82316283200.

Genexine generates an estimated annual revenue of $9,408,840. This revenue figure reflects the company's market position and business performance in its industry.

Genexine has an estimated valuation of $30,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Genexine was founded in 1999, making it 27 years old. The company has established itself as a significant player in its industry over this time.

Genexine has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at Genexine

Joo Hyoung Lee

Director

Eunho Choi

Director

4.8

40,000 users